公开(公告)号：WO2014053996A3

公开(公告)日：2014-04-10

申请号：PCT/IB2013/059045

申请日：2013-10-01

Applicant: NESTEC S.A.

Inventor： SINGH, Sharat ,  CHI-KWAN LING, Nicholas ,  WANG, Shui-Long ,  PRINCEN, Fred ,  WESTIN, Stefan ,  LOCKTON, Steven

IPC: G01N33/564 ,  G01N33/569

Abstract: The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether a sample from an individual is an IBS sample or a healthy control sample using a statistical algorithm. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.

公开(公告)号：WO2016088104A2

公开(公告)日：2016-06-09

申请号：PCT/IB2015/059381

申请日：2015-12-04

Applicant: NESTEC S.A.

Inventor： SALBATO, Jared ,  WESTIN, Stefan ,  CHI-KWAN LING, Nicholas ,  JAIN, Anjali ,  SINGH, Sharat

IPC: G01N33/537 ,  G01N33/58 ,  G01N33/94

CPC classification number: G01N33/94 ,  C07K14/5434 ,  C07K14/70546 ,  C07K2319/20 ,  C07K2319/50 ,  G01N33/537 ,  G01N33/564 ,  G01N33/58 ,  G01N33/6854 ,  G01N2333/54 ,  G01N2333/5434 ,  G01N2333/70546 ,  G01N2800/065 ,  G01N2800/52

Abstract: The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or level of biologics that target complex or large antigens including cell surface proteins, transmembrane proteins, heavily glycosylated proteins, and multimeric proteins, as well as antigens that cannot be purified, impure antigens, and partially or substantially purified antigens. The present invention also provides isolated soluble α4β7 integrin heterodimers and isolated soluble IL-12p40 monomers that are suitable for use in the indirect assays described herein.

Abstract translation: 本发明提供了使用尺寸排阻色谱法来测量患者样品中的生物制剂如维多珠单抗和ustekinumab的敏感且特异性的间接均质迁移率变动测定。 本发明的测定法对于检测靶向包括细胞表面蛋白质，跨膜蛋白质，重度糖基化蛋白质和多聚体蛋白质的复合或大抗原的生物制剂的存在或水平是特别有利的，以及不能纯化的抗原，不纯的抗原 和部分或基本上纯化的抗原。 本发明还提供了适用于本文所述间接测定的分离的可溶性α4β7整联蛋白异二聚体和分离的可溶性IL-12p40单体。

公开(公告)号：WO2014188378A1

公开(公告)日：2014-11-27

申请号：PCT/IB2014/061636

申请日：2014-05-22

Applicant: NESTEC S.A.

Inventor： WESTIN, Stefan ,  SELVARAJ, Fabiyola ,  PRINCEN, Fred ,  SINGH, Sharat

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  C07D495/04 ,  C07D498/04 ,  C07D519/00 ,  C07K16/12 ,  C07K16/26 ,  C07K16/44 ,  C07K2317/33 ,  G01N33/6812 ,  G01N33/942 ,  G01N2800/065 ,  G01N2800/52

Abstract: The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether the individual does not have either celiac disease or inflammatory bowel disease (IBD), and has IBS and/or a subtype thereof. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.

Abstract translation: 本发明提供了帮助个体中肠易激综合征（IBS）诊断的方法。 特别地，本发明可用于确定个体是否不具有乳糜泻或炎症性肠病（IBD），并且具有IBS和/或其亚型。 因此，本发明提供了IBS的准确诊断预测，并且对于指导治疗决定是有用的。

公开(公告)号：WO2018130988A1

公开(公告)日：2018-07-19

申请号：PCT/IB2018/050212

申请日：2018-01-12

Applicant: NESTEC S.A.

Inventor： HALE, Michael ,  RIDEOUT, Darryl ,  SRIKRISHNAN, Raj ,  WESTIN, Stefan ,  SCHMIT, David

IPC: C07D487/08 ,  C07F5/00 ,  A61K49/00 ,  G01N33/533

Abstract: The present invention provides cryptates derivatives of formula (I) and conjugates thereof with excellent fluorescent properties. The cryptates are useful in biological assays and methods for the detection and identification of various analytes.